Loibl, Sibylle http://orcid.org/0000-0001-6488-4958
Huang, Chiun-Sheng http://orcid.org/0000-0002-6557-211X
Mano, Max S.
Mamounas, Eleftherios P.
Geyer, Charles E. Jr http://orcid.org/0000-0002-2379-5702
Untch, Michael
Thery, Jean-Christophe
Schwaner, Ingo
Limentani, Steven
Loman, Niklas
Lübbe, Kristina
Chang, Jenny C. http://orcid.org/0000-0002-0890-9302
Hatschek, Thomas
Tesarowski, David
Song, Chunyan
Lysbet de Haas, Sanne
Boulet, Thomas
Lambertini, Chiara
Wolmark, Norman
Funding for this research was provided by:
Roche
Article History
Received: 10 March 2022
Accepted: 23 August 2022
First Online: 19 September 2022
Competing interests
: Si.L. declares no competing non-financial Interests but the following competing financial Interests. Si.L. received research funding and/or honoraria for advisory boards and speaker roles paid to her institution from Abbvie, Amgen, AstraZeneca, Bristol-Myers-Squibb, Celgene, Daiichi Sankyo, EirGenix, Eli Lilly, F. Hoffmann-La Roche, GSK, Gilead, Medscape, Merck kG, Myriad Pharmaceuticals, Novartis, PEER, Pfizer, Pierre Fabre, Puma Biotechnology, Sanofi, and SeaGen. She holds several patents: EP14153692.0; EP21152186.9; EP15702464.7; EP19808852.8. GBG Forschungs GmbH receives royalties from VMscope. Si.L. is the CEO of the GBG Forschungs GmbH (GBG). C.-S.H. declares no competing non-financial Interests but the following competing financial Interests. He reports receiving research funding to his institution from AstraZeneca, Daiichi Sankyo, EirGenix, Eli Lilly, MSD, Novartis, OBI Pharma, Pfizer, and Roche; travel expenses from AstraZeneca, Pfizer, and Roche; and honoraria for advisory boards and speaker roles from Amgen, AstraZeneca, Eli Lilly, Novartis, Pfizer, and Roche. M.S.M. declares no competing non-financial Interests but the following competing financial Interests. He has owned stock in Biotoscana, Fleury, and Hypera. He reported receiving honoraria from Dasa, Lilly, Novartis, Oncologia Brasil, Pfizer, and Roche; and travel expenses from Roche. He has served as an advisor to AstraZeneca, Lilly, Novartis, Pfizer, and Roche. He has been a principal subinvestigator for clinical trials from Lilly, Novartis, Pfizer, and Roche. E.P.M. declares no competing non-financial Interests but the following competing financial Interests. He reports receiving honoraria from Biotheranostics, Daiichi Sankyo, Genentech/Roche, Genomic Health, and Merck; and research funding from the NSABP Foundation. C.E.G. declares no competing non-financial Interests but the following competing financial Interests. C.E.G. reports receiving consulting fees from Athenex, Celgene, Exact Science, Myriad Genetics, and Heron; uncompensated consulting for Daiichi Sankyo, Genentech, Roche, and Seattle Genetics; travel expenses from AstraZeneca, Daiichi Sankyo, Genentech, and Roche; and medical writing support from Abbvie and Roche. M.U. reported receiving honoraria from Odonate and PUMA Biotechnology, and non-financial support from Odonate. His institution has received fees and non-financial support from Abbvie, Amgen GmbH, AstraZeneca, Celgene GmbH, Clovis Oncology, Daiichi Sankyo, Eisai GmbH, Lilly Int., MSD Merck, Mundipharma, Myriad Genetics, Novartis, Pfizer GmbH, Roche Pharma AG, Sanofi Aventis Deutschland GmbH, and Teva Pharmaceuticals Ind Ltd. His institution has received fees from BMS, Pierre Fabre, and Lilly Deutschland. J.-C.T. declares no competing non-financial Interests but the following competing financial Interests. He reports receiving travel expenses from AstraZeneca, Esai, GSK, Mundi Pharma, Novartis, Pfizer, Pharmamar, and Roche; and research funding to his institution from Mundi Pharma. He serves as an advisor to Astra Zeneca and Pfizer. I.S. declares no competing non-financial Interests but the following competing financial Interests. He reports receiving travel expenses from Celgene, Janssen, Novartis, and Roche; and honoraria from Servier. He serves as an advisor to Abbvie, Amgen, Celgene, Hexal, Janssen, Novartis, Roche, and Servier. N.L. declares no competing non-financial Interests but the following competing financial Interests. He reports receiving honoraria from Astra Zeneca, MSD, Pierre Fabre, and Roche. K.L. declares no competing non-financial Interests but the following competing financial Interests. She reports receiving honoraria from Exact Science, Lilly, MSD, Novartis, Pfizer, and Roche for serving as an advisor. J.C.C. declares no competing non-financial Interests but the following competing financial Interests. She has served as an advisor to Celgene, Genentech, and Lilly. T.H. declares no competing non-financial Interests but the following competing financial Interests. He reports receiving travel expenses from Roche. He has served as an advisor to Pierre Fabre, Pfizer, and Roche. His institution has received research funding from Pfizer and Roche. D.T., C.S., and S.L.deH. declare no competing non-financial Interests but the following competing financial Interests. They own stock in and are employees of Roche. C.L. declares no competing non-financial Interests but the following competing financial Interests. She is an employee of Roche. T.B. declares no competing non-financial Interests but the following competing financial Interests. He is an employee of Parexel International GmbH contracted by Roche for statistical services in the conduct of the study. St. L. and N.W. declared no competing interests.